Arcturus Therapeutics (ARCT) Maintained at Neutral by H.C. Wainwright, Waiting for Pivotal Data for Arcturus' COVID-19 Vaccine Approval
Tweet Send to a Friend
H.C. Wainwright analyst Ed Arce reiterated a Neutral rating and $33.00 price target on Arcturus Therapeutics (NASDAQ: ARCT), following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE